🔎 Trials Near Me

Home › Clear-cell metastatic renal cell carcinoma › Illinois

Pag-aaral pangklinika para sa Clear-cell metastatic renal cell carcinoma sa Illinois

5 pag-aaral para sa Clear-cell metastatic renal cell carcinoma ang naghahanap ng mga kalahok sa mga site sa Illinois.

Mga Lungsod sa Illinois

Opisyal na teksto ng pag-aaral (English)

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

  • NEO-811 Chicago Site, Zion
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT07300241

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  • Research Site, Zion
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07011719

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  • Memorial Hospital, Shiloh
  • Siteman Cancer Center - Shiloh, Shiloh
  • City Of Hope - Chicago, Zion
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07227415

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

  • Illinois CancerCare-Bloomington, Bloomington
  • Illinois CancerCare-Canton, Canton
  • Illinois CancerCare-Carthage, Carthage
  • at 13 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 11, 2026 · NCT07383441

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

  • Saint Anthony's Health, Alton
  • Rush - Copley Medical Center, Aurora
  • Advocate Good Shepherd Hospital, Barrington
  • at 58 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2025 · NCT04510597

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.